V. Ellen Maher

2.1k citations

29 papers · 1.4k · h-index 17

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Immunology top 10%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 11
- Cancer Immunotherapy and Biomarkers 9
Pulmonary and Respiratory Medicine 9
- Prostate Cancer Treatment and Research 6
- Renal cell carcinoma treatment 3

Co-authors: Richard Pazdur (19 shared papers)Shenghui Tang (13 shared papers)Rajeshwari Sridhara (12 shared papers)Amna Ibrahim (12 shared papers)Yang‐Min Ning (11 shared papers)Geoffrey Kim (8 shared papers)Kirsten B. Goldberg (5 shared papers)Daniel L. Suzman (5 shared papers)
Journals: Journal of Clinical Oncology (11 papers)Clinical Cancer Research (4 papers)The Oncologist (4 papers)Journal of Immunotherapy (2 papers)Regulatory Toxicology and Pharmacology (1 paper)
Partner nations: United States Switzerland Jamaica

In The Last Decade

V. Ellen Maher

28 papers receiving 1.4k citations

Peers

Countries citing papers authored by V. Ellen Maher

Since Specialization

Citations

This map shows the geographic impact of V. Ellen Maher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Ellen Maher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Ellen Maher more than expected).

Fields of papers citing papers by V. Ellen Maher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Ellen Maher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Ellen Maher. The network helps show where V. Ellen Maher may publish in the future.

Co-authors

The 25 scholars most cited alongside V. Ellen Maher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with V. Ellen Maher Line = papers co-authored together V. Ellen Maher links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody Journal of Clinical Oncology ·V. Ellen Maher, Laura L. Fernandes, Chana Weinstock, Shenghui Tang, Sundeep Agarwal, Michael H. Brave, Yang‐Min Ning, Harpreet Singh, Daniel L. Suzman, James Xu, Kirsten B. Goldberg, Rajeshwari Sridhara, Amna Ibrahim, Marc R. Theoret, Julia A. Beaver, Richard Pazdur	2019	235
2	FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy The Oncologist ·Daniel L. Suzman, Sundeep Agrawal, Yang‐Min Ning, V. Ellen Maher, Laura L. Fernandes, Stella Karuri, Shenghui Tang, Rajeshwari Sridhara, Jason Schroeder, Kirsten B. Goldberg, Amna Ibrahim, Amy E. McKee, Richard Pazdur, Julia A. Beaver	2018	141
3	Immunization With Mutantp53- andK-ras–Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome Journal of Clinical Oncology ·David P. Carbone, I. Frank Ciernik, Michael J. Kelley, Malcolm C. Smith, Sorena Nadaf, Denise Kavanaugh, V. Ellen Maher, Michael Stipanov, David Contois, Bruce E. Johnson, C D Pendleton, Burkhardt Seifert, Charley Carter, Elizabeth J. Read, Jay J. Greenblatt, Lois E. Top, Morris I. Kelsey, John D. Minna, Jay A. Berzofsky	2005	128
4	Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary Clinical Cancer Research ·Paul G. Kluetz, William F. Pierce, V. Ellen Maher, Hui Zhang, Shenghui Tang, Pengfei Song, Qi Liu, Martin T. Haber, Eldon E. Leutzinger, Ali Al‐Hakim, Wei Chen, Todd R. Palmby, Elleni Alebachew, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur	2013	126
5	FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy The Oncologist ·Yang‐Min Ning, Daniel L. Suzman, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Tiffany K. Ricks, Todd R. Palmby, Wentao Fu, Qi Liu, Kirsten B. Goldberg, Geoffrey Kim, Richard Pazdur	2017	113
6	U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non–Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive Clinical Cancer Research ·Shakun Malik, V. Ellen Maher, Karen E. Bijwaard, Robert L. Becker, Lijun Zhang, Shenghui Tang, Pengfei Song, Qi Liu, Anshu Marathe, Brenda J. Gehrke, Whitney S. Helms, Diane Hanner, Robert Justice, Richard Pazdur	2014	113
7	Hormonal Regulation of Collagen Synthesis in a Clonal Rat Osteosarcoma Cell Line* Endocrinology ·Barbara E. Kream, David W. Rowe, Mark D. Smith, V. Ellen Maher, Robert J. Majeska	1986	80
8	FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis The Oncologist ·James Xu, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Amna Ibrahim, Geoffrey Kim, Richard Pazdur	2017	78
9	FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. Journal of Clinical Oncology ·Harpreet Singh, Geoffrey Kim, V. Ellen Maher, Julia A. Beaver, Lee H. Pai-Scherf, Sanjeeve Balasubramaniam, Marc R. Theoret, Gideon M. Blumenthal, Richard Pazdur	2016	61
10	The Combination of Zidovudine and Interferon AIpha-2B in the Treatment of Adult T-Cell Leukemia/Lymphoma Leukemia & lymphoma ·Jeffrey D. White, Gilian Wharfe, Donn M. Stewart, V. Ellen Maher, Donald M. Eicher, Bert Herring, Michael A. Derby, Peta-Gay Jackson-Booth, Margaret Marshall, Daniel Lucy, Ashish Jain, Beverley Cranston, B Hanchard, Cathryn C. Lee, Lois E. Top, Thomas A. Fleisher, David Lee Nelson, T. A. Waldmann	2001	55
11	Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary Clinical Cancer Research ·Paul G. Kluetz, Yang‐Min Ning, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Debasis Ghosh, Robeena Aziz, Todd R. Palmby, Elimika Pfuma, Jeanne Fourie Zirkelbach, Nitin Mehrotra, Amy Tilley, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur	2013	49
12	Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary Clinical Cancer Research ·Yang‐Min Ning, William F. Pierce, V. Ellen Maher, Stella Karuri, Shenghui Tang, Haw-Jyh Chiu, Todd R. Palmby, Jeanne Fourie Zirkelbach, Dhananjay Marathe, Nitin Mehrotra, Qi Liu, Debasis Ghosh, Christy L. Cottrell, John K. Leighton, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur	2013	39
13	Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy Cytotherapy ·Eitan Wong, V. Ellen Maher, Kenneth Hines, J. Lee, C.S. Carter, Theresa J. Goletz, William Kopp, Crystal L. Mackall, Jay A. Berzofsky, E.J. Read	2001	39
14	U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer The Oncologist ·Yang‐Min Ning, Michael H. Brave, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Geoffrey Kim, Amna Ibrahim, Richard Pazdur	2015	36
15	Mice infected with develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor Microbes and Infection ·Margaret Marshall, Dragana Janković, V. Ellen Maher, Alan Sher, Jay A. Berzofsky	2001	29
16	Simultaneous chronic lymphocytic leukemia and chronic myelogenous leukemia. Evidence of a separate stem cell origin Cancer ·V. Ellen Maher, Lisa Gill, Philip L. Townes, Janice E. Wallace, Louis Savas, Bruce A. Woda, Jack Ansell	1993	19
17	FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents. Journal of Clinical Oncology ·Chana Weinstock, Harpreet Singh, V. Ellen Maher, Geoffrey Kim, Richard Pazdur	2017	19
18	Human Antibody Response to the Intravenous and Intraperitoneal Administration of the F(ab')2 Fragment of the OC125 Murine Monoclonal Antibody Journal of Immunotherapy ·V. Ellen Maher, Susan J. Drukman, Robert J. Kinders, Richard E. Hunter, Jean Jennings, Christine Brigham, S. Steven, Thomas W. Griffin	1992	16
19	Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer Bladder Cancer ·Jonathan P. Jarow, V. Ellen Maher, Shenghui Tang, Amna Ibrahim, Geoffrey Kim, Rajeshwari Sridhara, Richard Pazdur	2015	13
20	Combined Antitumor Therapy with the Chemotherapeutic Drug Doxorubicin and an Anti-Transferrin Receptor Immunotoxin, In Vitro and In Vivo Studies Journal of Immunotherapy ·Thomas W. Griffin, M. Stocl, Jerry M. Collins, J. Fernandes, V. Ellen Maher	1992	9

About V. Ellen Maher

V. Ellen Maher is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Radiology, Nuclear Medicine and Imaging and Economics and Econometrics, having authored 29 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Bladder and Urothelial Cancer Treatments (8 papers), Prostate Cancer Treatment and Research (6 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers), Renal cell carcinoma treatment (3 papers), Cancer, Lipids, and Metabolism (3 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Oncology (680 citations), Immunology (328 citations), Pulmonary and Respiratory Medicine (388 citations), Cancer Research (108 citations) and Radiology, Nuclear Medicine and Imaging (152 citations). V. Ellen Maher has collaborated with scholars based in United States, Switzerland and Jamaica. Frequent co-authors include Richard Pazdur, Shenghui Tang, Rajeshwari Sridhara, Amna Ibrahim, Yang‐Min Ning, Geoffrey Kim, Kirsten B. Goldberg, Daniel L. Suzman, Julia A. Beaver and James Xu. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, The Oncologist, Journal of Immunotherapy and Regulatory Toxicology and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

V. Ellen Maher

Impact in

Papers in i

In The Last Decade

V. Ellen Maher

Peers

Countries citing papers authored by V. Ellen Maher

Fields of papers citing papers by V. Ellen Maher

All Works

About V. Ellen Maher

Explore authors with similar magnitude of impact

Papers in